Grant No. ACZ885M 2301 A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction patients with elevated hsCRP

Project: Other project

StatusFinished
Effective start/end date1/1/121/31/17

Funding

  • Novartis Pharmaceuticals Corporation: $5,280.00